TALLAHASSEE, Fla., Nov. 5, 2025
TALLAHASSEE, Fla., Nov. 5, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended September 30, 2025. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles (GAAP), unless otherwise indicated. Numbers may not sum perfectly due to rounding.
Q3 2025 Financial and Operational Highlights*
*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Recent Developments
Management Commentary
"Our 2025 strategic plan is delivering results, with demonstrable progress on reform, customers, distribution, and branded products," said Kim Rivers, Trulieve CEO. "Significant flexibility in our core business and strong cash generation continue to set us apart in a dynamic market."
Financial Highlights*
| Results of Operations | For the Three Months Ended | For the Nine Months Ended | ||||||||||||
| (Figures in millions except per share data) | September | September | % | June 30, | % | September | September | % | ||||||
| Revenue | $ | 288 | $ | 284 | 1 % | $ | 302 | (5 %) | $ | 888 | $ | 885 | — % | |
| Gross profit | $ | 170 | $ | 173 | (2 %) | $ | 183 | (7 %) | $ | 536 | $ | 529 | 1 % | |
| Gross margin % | | 59 % | | 61 % | | | 61 % | | | 60 % | | 60 % | | |
| Operating expenses | $ | 128 | $ | 173 | 26 % | $ | 130 | 2 % | $ | 408 | $ | 432 | 6 % | |
| Operating expenses % | | 44 % | | 61 % | | | 43 % | | | 46 % | | 49 % | | |
| Net loss** | $ | (27) | $ | (60) | 55 % | $ | (14) | (95 %) | $ | (73) | $ | (95) | 23 % | |
| Net loss continuing | $ | (24) | $ | (60) | 61 % | $ | (16) | (50 %) | $ | (72) | $ | (94) | 24 % | |
| Adjusted net (loss) income | $ | (12) | $ | (12) | (5 %) | $ | (8) | (61 %) | $ | (24) | $ | (22) | (8 %) | |
| Basic and diluted shares | | 191 | | 190 | | | 191 | | | 191 | | 190 | | |
| EPS continuing operations | $ | (0.11) | $ | (0.32) | 64 % | $ | (0.07) | (62 %) | $ | (0.35) | $ | (0.52) | 34 % | |
| Adjusted EPS | $ | (0.07) | $ | (0.06) | (5 %) | $ | (0.04) | (61 %) | $ | (0.12) | $ | (0.12) | (7 %) | |
| Adjusted EBITDA | $ | 103 | $ | 96 | 7 % | $ | 111 | (7 %) | $ | 322 | $ | 309 | 4 % | |
| Adjusted EBITDA Margin % | | 36 % | | 34 % | | | 37 % | | | 36 % | | 35 % | | |
| | | | | | | | | | | | | | | |
| *See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics. |
| **Net loss attributable to common shareholders which excludes non-controlling interest. |
Conference Call
The Company will host a conference call and live audio webcast on November 5, 2025, at 8:30 A.M. Eastern time, to discuss its third quarter 2025 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.
| North American toll free: 1-844-824-3830 | | Passcode: 9870622 |
| | | |
| International: 1-412-542-4136 | | Passcode: 9870622 |
A live audio webcast of the conference call will be available at: Trulieve Third Quarter 2025 Results Call
A powerpoint presentation and archived replay of the webcast will be available at: https://investors.trulieve.com/events
The Company's Form 10-Q for the quarter ended September 30, 2025 will be available on the SEC's website or at https://investors.trulieve.com/quarterly-results. The Company's Management's Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company's profile on https://www.sedarplus.ca and on its website at https://investors.trulieve.com/quarterly-results. This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.
| Trulieve Cannabis Corp. Condensed Consolidated Balance Sheets (Unaudited) (in millions, except for share data) | |||
| | |||
| | September 30, | | December 31, |
| ASSETS | | | |
| Current Assets: | | | |
| Cash and cash equivalents | $ 449.2 | | $ 238.8 |
| Short-term investments | — | | 60.4 |
| Restricted cash - current | 0.9 | | 0.9 |
| Accounts receivable, net | 10.5 | | 8.3 |
| Inventories | 243.3 | | 231.4 |
| Income tax receivable | 7.4 | | 10.0 |
| Prepaid expenses | 20.7 | | 23.0 |
| Other current assets | 22.1 | | 26.2 |
| Notes receivable - current portion, net | 1.6 | | 4.8 |
| Assets associated with discontinued operations | 0.9 | | 0.9 |
| Total current assets | 756.4 | | 604.6 |
| Property and equipment, net | 694.0 | | 716.1 |
| Right of use assets - operating, net | 110.7 | | 119.5 |
| Right of use assets - finance, net | 60.9 | | 64.4 |
| Intangible assets, net | 815.3 | | 859.5 |
| Goodwill | 483.9 | | 483.9 |
| Restricted cash | 7.5 | | — |
| Notes receivable, net | 0.5 | | 0.5 |
| Other assets | 10.4 | | 19.8 |
| Long-term assets associated with discontinued operations | 1.9 | | 2.0 |
| TOTAL ASSETS | $ 2,941.6 | | $ 2,870.3 |
| LIABILITIES | | | |
| Current Liabilities: | | | |
| Accounts payable and accrued liabilities | $ 81.3 | | $ 94.0 |
| Deferred revenue | 8.9 | | 8.0 |
| Notes payable - current portion | 3.7 | | 3.4 |
| Operating lease liabilities - current portion | 12.8 | | 12.1 |
| Finance lease liabilities - current portion | 10.4 | | 9.5 |
| Construction finance liabilities - current portion | 2.3 | | 1.9 |
| Contingencies | 0.8 | | 6.3 |
| Liabilities associated with discontinued operations | 3.9 | | 3.1 |
| Total current liabilities | 124.1 | | 138.5 |
| Long-Term Liabilities: | | | |
| Private placement notes, net | 366.1 | | 364.8 |
| Notes payable, net | 107.7 | | 111.9 |
| Operating lease liabilities | 110.5 | | 117.5 |
| Finance lease liabilities | 65.2 | | 67.7 |
| Construction finance liabilities | 134.3 | | 135.5 |
| Deferred tax liabilities | 181.9 | | 196.5 |
| Uncertain tax position liabilities | 616.3 | | 445.2 |
| Other long-term liabilities | 11.8 | | 5.0 |
| Long-term liabilities associated with discontinued operations | 37.4 | | 38.6 |
| TOTAL LIABILITIES | $ 1,755.3 | | $ 1,621.2 |
| SHAREHOLDERS' EQUITY | | | |
| Common stock, no par value; unlimited shares authorized. 191,144,583 and | $ — | | $ — |
| Additional paid-in-capital | 2,073.0 | | 2,057.0 |
| Accumulated deficit | (869.2) | | (795.7) |
| Non-controlling interest | (17.5) | | (12.3) |
| TOTAL SHAREHOLDERS' EQUITY | 1,186.3 | | 1,249.0 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 2,941.6 | | $ 2,870.3 |
| Trulieve Cannabis Corp. Condensed Consolidated Statements of Operations (Unaudited) (in millions, except for share data) | |||||||
| | |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| Revenue | $ 288.2 | | $ 284.3 | | $ 888.0 | | $ 885.3 |
| Cost of goods sold | 118.3 | | 111.0 | | 352.0 | | 356.6 |
| Gross profit | 169.9 | | 173.3 | | 536.0 | | 528.7 |
| Expenses: | | | | | | | |
| Selling, general, and administrative | 99.0 | | 148.6 | | 318.9 | | 352.5 |
| Depreciation and amortization | 29.5 | | 28.3 | | 88.2 | | 84.2 |
| Impairment and other charges, net of (recoveries) | (0.9) | | (4.3) | | 0.7 | | (4.4) |
| Total expenses | 127.6 | | 172.7 | | 407.8 | | 432.3 |
| Income from operations | 42.2 | | 0.6 | | 128.2 | | 96.5 |
| Other income (expense): | | | | | | | |
| Interest expense, net | (16.1) | | (17.5) | | (48.8) | | (47.6) |
| Interest income | 4.4 | | 4.2 | | 11.1 | | 11.5 |
| Other expense, net | (1.2) | | (0.2) | | (2.0) | | (4.8) |
| Total other expense, net | (12.9) | | (13.5) | | (39.7) | | (40.9) |
| Income (loss) before provision for income taxes | 29.3 | | (12.8) | | 88.5 | | 55.6 |
| Provision for income taxes | 53.0 | | 47.4 | | 160.2 | | 150.0 |
| Net loss from continuing operations | (23.7) | | (60.2) | | (71.7) | | (94.4) |
| Net loss from discontinued operations, net of tax benefit (provision) of $0, $0, | (5.0) | | (1.6) | | (7.0) | | (4.6) |
| Net loss | (28.8) | | (61.9) | | (78.7) | | (99.0) |
| Less: net loss attributable to non-controlling interest from continuing operations | (1.9) | | (1.7) | | (5.2) | | (3.7) |
| Net loss attributable to common shareholders | $ (26.8) | | $ (60.2) | | $ (73.5) | | $ (95.3) |
| | | | | | | | |
| Earnings Per Share | | | | | | | |
| Net loss per share - Continuing operations: | | | | | | | |
| Basic and diluted | $ (0.11) | | $ (0.32) | | $ (0.35) | | $ (0.52) |
| Net loss per share - Discontinued operations: | | | | | | | |
| Basic and diluted | $ (0.03) | | $ (0.01) | | $ (0.04) | | $ (0.02) |
| Weighted average number of common shares used in computing net loss per | | | | | | | |
| Basic and diluted | 191.2 | | 190.2 | | 191.2 | | 190.0 |
| Trulieve Cannabis Corp. Condensed Consolidated Statements of Cash Flows (Unaudited) (in millions) | |||||||
| | |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| Cash flows from operating activities | | | | | | | |
| Net loss | $ (28.8) | | $ (61.9) | | $ (78.7) | | $ (99.0) |
| Adjustments to reconcile net loss to net cash provided by operating | | | | | | | |
| Depreciation and amortization | 29.5 | | 28.3 | | 88.2 | | 84.2 |
| Depreciation included in cost of goods sold | 13.9 | | 13.3 | | 41.5 | | 40.1 |
| Impairment and other charges, net of (recoveries) | 2.6 | | (4.3) | | 2.5 | | (4.4) |
| Share-based compensation | 5.8 | | 5.5 | | 16.5 | | 15.6 |
| Deferred income taxes | (4.7) | | (6.2) | | (14.7) | | (2.7) |
| Other non-cash changes | 3.7 | | 3.2 | | 16.0 | | 14.1 |
| Changes in operating assets and liabilities: | | | | | | | |
| Inventories | (1.8) | | (13.3) | | (11.9) | | (8.3) |
| Accounts receivable | — | | (1.5) | | (3.4) | | (0.7) |
| Other assets | 4.7 | | 3.8 | | 3.3 | | (7.0) |
| Accounts payable and accrued liabilities | 0.3 | | 4.9 | | (11.6) | | 4.6 |
| Income tax receivable / payable | (0.1) | | 0.5 | | 2.6 | | (4.3) |
| Other liabilities | (4.9) | | 2.5 | | (13.7) | | (1.1) |
| Uncertain tax position liabilities | 56.6 | | 51.0 | | 171.1 | | 203.8 |
| Proceeds received from insurance for operating expenses | — | | 4.4 | | 5.7 | | 5.9 |
| Net cash provided by operating activities | 76.8 | | 30.3 | | 213.6 | | 240.8 |
| Cash flows from investing activities | | | | | | | |
| Purchases of property and equipment | (12.3) | | (38.1) | | (40.8) | | (79.9) |
| Purchases of internal use software | (4.3) | | (6.8) | | (12.6) | | (18.3) |
| Purchases of short-term investments | — | | (80.0) | | — | | (80.0) |
| Maturities of short-term investments | (0.4) | | — | | 60.0 | | — |
| Other purchases and payments | 0.1 | | (7.1) | | (0.1) | | (7.6) |
| Other proceeds | 1.5 | | 0.5 | | 12.9 | | 2.4 |
| Net cash provided by (used in) investing activities | (15.4) | | (131.5) | | 19.4 | | (183.4) |
| Cash flows from financing activities | | | | | | | |
| Payments on long-term borrowings | (2.0) | | (2.3) | | (7.5) | | (6.4) |
| Payments for taxes related to net share settlement of equity awards | (0.2) | | (12.2) | | (0.5) | | (12.3) |
| Other payments and distributions | (2.6) | | (1.9) | | (7.1) | | (11.7) |
| Proceeds from equity exercises | — | | — | | — | | 0.2 |
| Other proceeds | — | | — | | — | | 3.0 |
| Net cash used in financing activities | (4.8) | | (16.4) | | (15.1) | | (27.1) |
| Net increase in cash, cash equivalents, and restricted cash | 56.6 | | (117.5) | | 217.9 | | 30.3 |
| Cash, cash equivalents, and restricted cash, beginning of period | 401.0 | | 356.1 | | 239.7 | | 208.0 |
| Cash and cash equivalents of discontinued operations, beginning of period | — | | — | | — | | 0.3 |
| Less: cash and cash equivalents of discontinued operations, end of period | — | | — | | — | | — |
| Cash, cash equivalents, and restricted cash, end of period | $ 457.6 | | $ 238.6 | | $ 457.6 | | $ 238.6 |
The condensed consolidated statements of cash flows include continuing operations and discontinued operations for the periods presented.
Non-GAAP Financial Measures (Unaudited)
In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, adjusted net (loss) income, adjusted net (loss) income per diluted share, and free cash flow.
The Company calculates EBITDA as net income (loss) before net interest expense, interest income, income tax expense, depreciation and amortization; adjusted EBITDA as net income (loss) before net interest expense, interest income, income tax expense, depreciation and amortization and also excludes certain extraordinary items; EBITDA margin as EBITDA as % of revenue; adjusted EBITDA margin as adjusted EBITDA as % of revenue; adjusted net income (loss) as net income (loss) less certain extraordinary items; adjusted EPS as adjusted net income (loss) divided by basic and diluted shares outstanding; and free cash flow as cash flow from operations less capital expenditures.
Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures are not, and should not be considered as, measures of liquidity. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.
Reconciliation of Non-GAAP EBITDA and Adjusted EBITDA (Unaudited)
The following table presents a reconciliation of GAAP net loss attributable to common shareholders to non-GAAP EBITDA and Adjusted EBITDA for each of the periods presented:
| (Amounts expressed in millions of United States dollars) | Three Months Ended | For the Nine Months Ended | ||||||||
| September | September | June 30, | September | September | ||||||
| Net loss attributable to common shareholders | $ | (26.8) | $ | (60.2) | $ | (13.8) | $ | (73.5) | $ | (95.3) |
| Add (deduct) impact of: | | | | | | | | | | |
| Interest expense, net | $ | 16.1 | $ | 17.5 | $ | 16.4 | $ | 48.8 | $ | 47.6 |
| Interest income | $ | (4.4) | $ | (4.2) | $ | (3.6) | $ | (11.1) | $ | (11.5) |
| Provision for income taxes | $ | 53.0 | $ | 47.4 | $ | 54.7 | $ | 160.2 | $ | 150.0 |
| Depreciation and amortization | $ | 29.5 | $ | 28.3 | $ | 29.4 | $ | 88.2 | $ | 84.2 |
| Depreciation included in cost of goods sold | $ | 13.9 | $ | 13.3 | $ | 13.7 | $ | 41.5 | $ | 40.1 |
| EBITDA (Non-GAAP) | $ | 81.3 | $ | 42.1 | $ | 96.8 | $ | 254.1 | $ | 215.0 |
| EBITDA Margin (Non-GAAP) | | 28 % | | 15 % | | 32 % | | 29 % | | 24 % |
| | | | | | | | | | | |
| Impairment and other charges, net of (recoveries) | $ | (0.9) | $ | (4.3) | $ | (0.3) | $ | 0.7 | $ | (4.4) |
| Campaign and political contributions | $ | 6.3 | $ | 48.4 | $ | 4.4 | $ | 33.7 | $ | 62.7 |
| Acquisition, transaction, and other non-recurring costs | $ | 3.8 | $ | 2.6 | $ | 1.6 | $ | 8.5 | $ | 10.6 |
| Share-based compensation | $ | 5.8 | $ | 5.5 | $ | 6.8 | $ | 16.5 | $ | 15.6 |
| Other expense (income), net | $ | 1.2 | $ | 0.2 | $ | 1.0 | $ | 2.0 | $ | 4.8 |
| Discontinued operations, net of tax, attributable to | $ | 5.0 | $ | 1.6 | $ | 0.3 | $ | 7.0 | $ | 4.6 |
| Adjusted EBITDA (Non-GAAP) | $ | 102.7 | $ | 96.1 | $ | 110.6 | $ | 322.5 | $ | 308.8 |
| Adjusted EBITDA Margin (Non-GAAP) | | 36 % | | 34 % | | 37 % | | 36 % | | 35 % |
Reconciliation of Non-GAAP Adjusted Net (Loss) Income (Unaudited)
The following table presents a reconciliation of GAAP net loss attributable to common shareholders to non-GAAP adjusted net (loss) income, for each of the periods presented:
| | For the Three Months Ended | For the Nine Months Ended | ||||||||
| (Amounts expressed in millions of United States dollars) | September | September | June 30, | September | September | |||||
| Net loss attributable to common shareholders | $ | (26.8) | $ | (60.2) | $ | (13.8) | $ | (73.5) | $ | (95.3) |
| Net loss from discontinued operations, net of tax, | $ | 5.0 | $ | 1.6 | $ | 0.3 | $ | 7.0 | $ | 4.6 |
| Adjustment of formerly redeemable non-controlling | $ | — | $ | (2.1) | $ | — | $ | — | $ | (9.0) |
| Net loss from continuing operations available to common | $ | (21.8) | $ | (60.6) | $ | (13.5) | $ | (66.5) | $ | (99.7) |
| Add (deduct) impact of: | | | | | | | | | | |
| Adjustment of formerly redeemable non-controlling | $ | — | $ | 2.1 | $ | — | $ | — | $ | 9.0 |
| Impairment and other charges, net of (recoveries) | $ | (0.9) | $ | (4.3) | $ | (0.3) | $ | 0.7 | $ | (4.4) |
| Campaign and political contributions | $ | 6.3 | $ | 48.4 | $ | 4.4 | $ | 33.7 | $ | 62.7 |
| Acquisition, transaction, and other non-recurring costs | $ | 3.8 | $ | 2.6 | $ | 1.6 | $ | 8.5 | $ | 10.6 |
| Adjusted net (loss) income (Non-GAAP) | $ | (12.5) | $ | (11.9) | $ | (7.7) | $ | (23.6) | $ | (21.9) |
Reconciliation of Non-GAAP Adjusted Net (Loss) Income Per Diluted Share (Unaudited)
The following table presents a reconciliation of GAAP net loss attributable to common shareholders per share to non-GAAP adjusted net (loss) income per diluted share, for each of the periods presented:
| | For the Three Months Ended | For the Nine Months Ended | ||||||||
| (Amounts expressed are per share except for shares | September | September | June 30, | September | September | |||||
| Net loss attributable to common shareholders | $ | (0.14) | $ | (0.32) | $ | (0.07) | $ | (0.38) | $ | (0.50) |
| Net loss from discontinued operations, net of tax, | $ | 0.03 | $ | 0.01 | $ | 0.00 | $ | 0.04 | $ | 0.02 |
| Adjustment of formerly redeemable non-controlling | $ | — | $ | (0.01) | $ | — | $ | — | $ | (0.05) |
| Net loss from continuing operations available to common | $ | (0.11) | $ | (0.32) | $ | (0.07) | $ | (0.35) | $ | (0.52) |
| Add (deduct) impact of: | | | | | | | | | | |
| Adjustment of formerly redeemable non-controlling | $ | — | $ | 0.01 | $ | — | $ | — | $ | 0.05 |
| Impairment and other charges, net of (recoveries) Für dich aus unserer Redaktion zusammengestelltDein Kommentar zum Artikel im Forum Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Weitere Artikel des AutorsThemen im Trend | ||||||||||